Developer docs
API playgroundTry for free, no card

Search company profiles

Cogstate Ltd.

Full company profile

uuid002ml1a

Namestring
Cogstate Ltd.
Legal namestring
Cogstate Limited
Websiteurl
cogstate.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Cogstate Ltd. is a publicly traded (ASX: CGS, OTC: COGZF) digital cognitive assessment company that builds and commercializes validated electronic cognitive testing batteries, rater training programs, and monitoring solutions for use in central nervous system (CNS) clinical trials. The company's platform delivers cognitive assessments through a unified electronic clinical outcome assessment (eCOA) architecture that supports both site-based and decentralized trial environments, and is positioned as one of three primary global platform providers alongside Pearson Clinical Assessment and Cambridge Cognition. Its core technology stack emphasizes accuracy, endpoint integrity, and regulatory-grade validation across indications including early-stage Alzheimer's, broader CNS disorders, sleep medicine, and Long COVID.

The company sells primarily to enterprise pharmaceutical and biotechnology sponsors conducting CNS clinical trials, as well as clinical research organizations (CROs) that operationalize those trials. Cogstate generates revenue through contract-based clinical trial services that are recurring in nature, with pricing quote-based and not publicly disclosed. Its go-to-market combines direct enterprise field sales targeting pharma/biotech sponsors with strategic channel partnerships, most notably the integration of its assessments into Medidata's unified eCOA platform and THREAD's decentralized research platform, both formalized in 2024. Cogstate also invests in thought leadership, with Chief Innovation Officer Prof. Paul Maruff presenting frameworks for cognitive endpoint selection at industry webinars.

Operationally, Cogstate is headquartered in New Haven, United States, employs between 101 and 250 people, and reported a 12% year-over-year revenue increase in Q2 2026 alongside record trial starts and an expanded customer base, while maintaining strong financial margins. Leadership comprises CEO Brad O'Connor, CTO Ben Bloomfield, CFO Darren Watson, Chief Commercial Officer Kenneth Billard, Chief Scientific Officer Chris Edgar, and Chief Innovation Officer Prof. Paul Maruff.

Short descriptiontext

Cogstate Ltd. builds validated digital cognitive assessments, rater training, and eCOA solutions for pharmaceutical, biotech, and CRO customers running CNS clinical trials, distributing through Medidata and THREAD integrations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
digital cognitive assessment, clinical outcome assessments, CNS clinical trials, eCOA platform, decentralized clinical trials
Industry4 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLACAOAD
Clinical Trial Management Systems (CTMS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Testing Laboratories and Services54138
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Cognitive Assessment Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services
TypeSubscription Recurring
Description

Revenue generated from pharmaceutical and biotech companies contracting for cognitive assessment services in clinical trials, with 12% revenue increase in Q2 2026 driven by growth in clinical trial contracts and diversification into new therapeutic indications.

seekingalpha.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Cogstate designs and delivers validated digital cognitive assessments paired with rater training and monitoring solutions that are integrated into electronic Clinical Outcome Assessment (eCOA) platforms used in central nervous system (CNS) clinical trials. Its solutions support pharmaceutical, biotech, and CRO customers running decentralized trials across therapeutic areas such as Alzheimer's disease and sleep-wakefulness disorders. The company combines proprietary assessment batteries, eCOA delivery technology, and clinical-development expertise as a contracted service to trial sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced variability and administrative burden in CNS clinical trials
+1 more record
Product and service4 records
1Validated Digital Cognitive Assessments
CategoryCognitive assessment software
Description

Validated digital cognitive assessments delivered to pharmaceutical, biotech, and CRO customers for use in central nervous system (CNS) clinical trials, designed to preserve endpoint integrity and data quality across sites.

2Rater Training and Monitoring Solutions
CategoryClinical trial rater services
Description

Comprehensive rater training and monitoring solutions used by clinical trial sponsors to ensure cognitive assessment consistency and endpoint quality across global CNS trial sites.

3Decentralized eCOA Delivery for CNS Trials
CategoryeCOA platform delivery
Description

Flexible electronic Clinical Outcome Assessment delivery supporting decentralized CNS clinical trial environments, enabling broader reach and site flexibility for trial sponsors.

4Cognitive Framework for Sleep-Wakefulness Drug Evaluation
CategorySleep medicine cognitive assessment
Description

A domain-specialized cognitive assessment framework that addresses inconsistent terminology and aligns subjective and objective cognitive measurement for sleep medicine clinical development teams.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-01
Description

Strategic partnership integrating Cogstate's validated digital cognitive assessments, rater training, and monitoring solutions into Medidata's unified eCOA platform. A case study involving a Long COVID study conducted with a clinical-stage biopharmaceutical company demonstrated how consolidating multiple assessment types onto a single device streamlined site operations and improved data integrity.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-01
Description

Partnership to combine Cogstate's digital assessment capabilities with THREAD's decentralized research platforms for central nervous system disorders, enabling more flexible eCOA delivery in decentralized trial environments.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1THREAD, Inc.
TypeEmerging player
Description

Decentralized clinical trial platform partner (announced Jul 2024); both an integration partner and an emerging platform competitor in decentralized CNS trial delivery.

TypeEmerging player
Description

Emerging player in CNS clinical research services providing imaging biomarkers and CNS trial support for neurodegenerative disease programs, partially overlapping Cogstate's CNS trial endpoint focus.

TypeBroad incumbent
Description

Global CRO and clinical technology provider offering eCOA, CNS trial services, and decentralized trial platforms; represents both a large competitor and potential enterprise customer for cognitive assessment solutions.

TypeBroad incumbent
Description

Large CRO providing clinical outcome assessment and CNS endpoint services for pharmaceutical sponsors; competes for similar pharma/biotech contracts with cognitive and functional endpoint offerings.

TypeBroad incumbent
Description

Broad clinical trial technology incumbent providing eCOA, imaging, and CNS assessment solutions across multiple therapeutic areas; competes with Cogstate's eCOA-integrated cognitive assessment offering for enterprise pharma sponsors.

TypeDirect peer
Description

Direct competitor providing validated cognitive assessment solutions for clinical trials; named alongside Cogstate and Cambridge Cognition as one of the three primary global platform providers.

TypeDirect peer
Description

Direct competitor in digital cognitive assessment for CNS clinical trials; explicitly named alongside Cogstate as one of the three primary global platform providers in the cognitive assessment market.

TypeDirect peer
Description

Direct competitor offering eCOA, rater training, and CNS clinical outcome assessment services for pharmaceutical trials; overlaps with Cogstate's rater training and monitoring solutions in CNS indications.

TypeBroad incumbent
Description

Industry-leading eCOA and clinical trial technology platform; both a strategic partner (via integration) and a competitive threat if it expands its own cognitive assessment capabilities in CNS.

TypeBroad incumbent
Description

Clinical services provider offering CNS clinical trial solutions, rater training, and eCOA-related services that overlap with Cogstate's enterprise CNS assessment offering.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cogstate Ltd.

Clinical Trial Cognitive Assessment Softwarecogstate.com

Cogstate Ltd. builds validated digital cognitive assessments, rater training, and eCOA solutions for pharmaceutical, biotech, and CRO customers running CNS clinical trials, distributing through Medidata and THREAD integrations.

What Cogstate Ltd. does

Cogstate Ltd. is a publicly traded (ASX: CGS, OTC: COGZF) digital cognitive assessment company that builds and commercializes validated electronic cognitive testing batteries, rater training programs, and monitoring solutions for use in central nervous system (CNS) clinical trials. The company's platform delivers cognitive assessments through a unified electronic clinical outcome assessment (eCOA) architecture that supports both site-based and decentralized trial environments, and is positioned as one of three primary global platform providers alongside Pearson Clinical Assessment and Cambridge Cognition. Its core technology stack emphasizes accuracy, endpoint integrity, and regulatory-grade validation across indications including early-stage Alzheimer's, broader CNS disorders, sleep medicine, and Long COVID.

The company sells primarily to enterprise pharmaceutical and biotechnology sponsors conducting CNS clinical trials, as well as clinical research organizations (CROs) that operationalize those trials. Cogstate generates revenue through contract-based clinical trial services that are recurring in nature, with pricing quote-based and not publicly disclosed. Its go-to-market combines direct enterprise field sales targeting pharma/biotech sponsors with strategic channel partnerships, most notably the integration of its assessments into Medidata's unified eCOA platform and THREAD's decentralized research platform, both formalized in 2024. Cogstate also invests in thought leadership, with Chief Innovation Officer Prof. Paul Maruff presenting frameworks for cognitive endpoint selection at industry webinars.

Operationally, Cogstate is headquartered in New Haven, United States, employs between 101 and 250 people, and reported a 12% year-over-year revenue increase in Q2 2026 alongside record trial starts and an expanded customer base, while maintaining strong financial margins. Leadership comprises CEO Brad O'Connor, CTO Ben Bloomfield, CFO Darren Watson, Chief Commercial Officer Kenneth Billard, Chief Scientific Officer Chris Edgar, and Chief Innovation Officer Prof. Paul Maruff.

Cogstate Ltd. firmographics

Firmographics
Name
Cogstate Ltd.
Legal name
Cogstate Limited
Website
https://cogstate.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Short description
Cogstate Ltd. builds validated digital cognitive assessments, rater training, and eCOA solutions for pharmaceutical, biotech, and CRO customers running CNS clinical trials, distributing through Medidata and THREAD integrations.
Ownership category
akta.pro rank

Cogstate Ltd. industry classification

Industry
Product category
Clinical Trial Cognitive Assessment Software
NAICS
Scientific Research and Development Services (5417), Testing Laboratories and Services (54138), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLACAOAD
Clinical Trial Management Systems (CTMS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Digital cognitive assessment
  • Clinical outcome assessments
  • CNS clinical trials
  • ECOA platform
  • Decentralized clinical trials

Where Cogstate Ltd. is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Cogstate Ltd. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Clinical Trial Services: Revenue generated from pharmaceutical and biotech companies contracting for cognitive assessment services in clinical trials, with 12% revenue increase in Q2 2026 driven by growth in clinical trial contracts and diversification into new therapeutic indications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Cogstate Ltd. product offering

Product offering

Core offering

Cogstate designs and delivers validated digital cognitive assessments paired with rater training and monitoring solutions that are integrated into electronic Clinical Outcome Assessment (eCOA) platforms used in central nervous system (CNS) clinical trials. Its solutions support pharmaceutical, biotech, and CRO customers running decentralized trials across therapeutic areas such as Alzheimer's disease and sleep-wakefulness disorders. The company combines proprietary assessment batteries, eCOA delivery technology, and clinical-development expertise as a contracted service to trial sponsors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Validated Digital Cognitive Assessments Validated digital cognitive assessments delivered to pharmaceutical, biotech, and CRO customers for use in central nervous system (CNS) clinical trials, designed to preserve endpoint integrity and data quality across sites.
  • Rater Training and Monitoring Solutions Comprehensive rater training and monitoring solutions used by clinical trial sponsors to ensure cognitive assessment consistency and endpoint quality across global CNS trial sites.
  • Decentralized eCOA Delivery for CNS Trials Flexible electronic Clinical Outcome Assessment delivery supporting decentralized CNS clinical trial environments, enabling broader reach and site flexibility for trial sponsors.
  • Cognitive Framework for Sleep-Wakefulness Drug Evaluation A domain-specialized cognitive assessment framework that addresses inconsistent terminology and aligns subjective and objective cognitive measurement for sleep medicine clinical development teams.

Quantifiable outcome

  • Reduced variability and administrative burden in CNS clinical trials
  • +1 more outcomes

Companies that use Cogstate Ltd.

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Cogstate Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cogstate Ltd. partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • MedidatacoreTechnology or Integration · 1 October 2024Strategic partnership integrating Cogstate's validated digital cognitive assessments, rater training, and monitoring solutions into Medidata's unified eCOA platform. A case study involving a Long COVID study conducted with a clinical-stage biopharmaceutical company demonstrated how consolidating multiple assessment types onto a single device streamlined site operations and improved data integrity.
  • THREAD, Inc.coreTechnology or Integration · 1 July 2024Partnership to combine Cogstate's digital assessment capabilities with THREAD's decentralized research platforms for central nervous system disorders, enabling more flexible eCOA delivery in decentralized trial environments.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Cogstate Ltd. competitors and assessment

Company assessment

Emerging players

  • THREAD, Inc. Decentralized clinical trial platform partner (announced Jul 2024); both an integration partner and an emerging platform competitor in decentralized CNS trial delivery.
  • Cerveau Technologies: Emerging player in CNS clinical research services providing imaging biomarkers and CNS trial support for neurodegenerative disease programs, partially overlapping Cogstate's CNS trial endpoint focus.

Broad incumbents

  • IQVIA: Global CRO and clinical technology provider offering eCOA, CNS trial services, and decentralized trial platforms; represents both a large competitor and potential enterprise customer for cognitive assessment solutions.
  • Evidera (PPD/Pharmaceutical Product Development): Large CRO providing clinical outcome assessment and CNS endpoint services for pharmaceutical sponsors; competes for similar pharma/biotech contracts with cognitive and functional endpoint offerings.
  • Clario: Broad clinical trial technology incumbent providing eCOA, imaging, and CNS assessment solutions across multiple therapeutic areas; competes with Cogstate's eCOA-integrated cognitive assessment offering for enterprise pharma sponsors.
  • Medidata Solutions: Industry-leading eCOA and clinical trial technology platform; both a strategic partner (via integration) and a competitive threat if it expands its own cognitive assessment capabilities in CNS.
  • WCG (WIRB-Copernicus Group): Clinical services provider offering CNS clinical trial solutions, rater training, and eCOA-related services that overlap with Cogstate's enterprise CNS assessment offering.

Direct peers

  • Pearson Clinical Assessment: Direct competitor providing validated cognitive assessment solutions for clinical trials; named alongside Cogstate and Cambridge Cognition as one of the three primary global platform providers.
  • Cambridge Cognition: Direct competitor in digital cognitive assessment for CNS clinical trials; explicitly named alongside Cogstate as one of the three primary global platform providers in the cognitive assessment market.
  • Signant Health (formerly MedAvante-ProPhase): Direct competitor offering eCOA, rater training, and CNS clinical outcome assessment services for pharmaceutical trials; overlaps with Cogstate's rater training and monitoring solutions in CNS indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cogstate Ltd. social profiles

Digital presence

Cogstate Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cogstate Ltd. leadership team

Management profile

Number of profiles

Profiles6 records

Cogstate Ltd. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cogstate Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cogstate Ltd.

What does Cogstate Ltd. do?

Cogstate designs and delivers validated digital cognitive assessments paired with rater training and monitoring solutions that are integrated into electronic Clinical Outcome Assessment (eCOA) platforms used in central nervous system (CNS) clinical trials. Its solutions support pharmaceutical, biotech, and CRO customers running decentralized trials across therapeutic areas such as Alzheimer's disease and sleep-wakefulness disorders. The company combines proprietary assessment batteries, eCOA delivery technology, and clinical-development expertise as a contracted service to trial sponsors.

Is Cogstate Ltd. a public or private company?

Cogstate Ltd. is a public company. It is classified as public and is currently operating.

When was Cogstate Ltd. founded?

Cogstate Ltd. was founded in 1999. It employs 251 to 500 people.

Where is Cogstate Ltd. based?

Cogstate Ltd. is headquartered in Melbourne, Australia, in the Oceania region.

How does Cogstate Ltd. make money?

One revenue line is on record: clinical Trial Services.

Who are Cogstate Ltd.'s main competitors?

Emerging players on record are THREAD, Inc. and Cerveau Technologies. Broad incumbents are IQVIA, Evidera (PPD/Pharmaceutical Product Development), Clario, Medidata Solutions and WCG (WIRB-Copernicus Group). Direct peers are Pearson Clinical Assessment, Cambridge Cognition and Signant Health (formerly MedAvante-ProPhase).

Does Cogstate Ltd. have an API?

No public API is recorded for Cogstate Ltd..

What industry is Cogstate Ltd. in?

Cogstate Ltd.'s product category is Clinical Trial Cognitive Assessment Software. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLACAOAD, Clinical Trial Management Systems (CTMS). Its NAICS code is 5417 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comCogstate at Bell Potter Healthcare Conference: medidata deal lifts outlookCogstate reported FY2026 revenue of $60.9 million with 25% EBIT margins and $35 million net cash. Its Medidata partnership helps win CNS trials, with contracted revenue of $143.7 million as of September 30, 2026. Management sees over 20% revenue growth ahead, though quarterly sales can swing sharply.Seeking AlphaCogstate Limited (COGZF) Q4 2026 Earnings Call TranscriptCogstate Limited released its Full Year Results for Financial Year '26, featuring a presentation by CEO Brad O'Connor and CFO Darren Watson. The earnings call transcript includes remarks from executive leadership regarding the company's performance.Investing.comCogstate FY26 slides: record contracts, AI investment amid revenue miss By Investing.comCogstate Limited reported FY26 full-year results featuring a record $89.0 million in new sales contracts and significant expansion in its clinical trial portfolio, despite reporting actual revenue of $21.85 million which missed analyst forecasts by nearly 50%. The company highlighted strong operational metrics including 15% year-over-year revenue growth to $60.9 million, a debt-free balance sheet with $34.8 million in cash, and a strategic two-year investment program to build an AI-enabled operating platform. Management provided guidance for FY27 expecting $48.3 million in contracted revenue recognition, attributing the recent quarterly miss to timing differences rather than demand deterioration.openPR.comCognition Enhancing Drugs Market CAGR 5.6 % innovations and key players Accelerated Intelligence Cognition Therapeutics Cogstate HVMN Biogen IdecThe cognition-enhancing drugs market is projected to grow at a 5.6% CAGR from 2025 to 2032, reaching a multibillion-dollar valuation. Growth is driven by rising demand for cognitive health, an aging population, and technological advancements like AI. Key players include Accelerated Intelligence, Cognition Therapeutics, Cogstate, HVMN, and Biogen Idec.YahooMedidata Sees Strong Momentum with Key Customer Wins, Advances in CNS and Digital Therapeutics, and Expanded Market LeadershipMedidata secured new enterprise agreements with a large pharma company, two top-10 biopharma manufacturers, and ICON, while advancing CNS and digital therapeutics partnerships with Cogstate and Click Therapeutics. The company also launched the Site Insights Program and integrated UK iCT data into Grants Manager, improving budget precision by up to 80%.Business InsiderAnalysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), COMPASS Pathways (CMPS) and Cogstate Ltd (OtherCOGZF)Analysts maintained bullish ratings on PTC Therapeutics, COMPASS Pathways, and Cogstate Ltd, with RBC Capital setting $60 and $15 targets respectively. PTC's consensus price target is $55.25, COMPASS's is $22.00, and Cogstate's is $0.91, implying upside from current levels.YahooMedidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced AnalyticsMedidata and Cogstate announced a partnership to transform clinical trials for CNS diseases, combining Medidata's eCOA and AI analytics with Cogstate's digital cognitive assessments. The collaboration aims to improve data quality, rater experience, and trial efficiency through a unified platform. The companies will present details at Medidata NEXT New York.Business Wire BlogMedidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced AnalyticsMedidata and Cogstate announced a strategic partnership to improve clinical trials for CNS diseases, combining Medidata's eCOA and AI analytics with Cogstate's digital cognitive assessments. The collaboration aims to enhance data quality, streamline rater workflows, and reduce study burden through a unified platform.GlobeNewswireCogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical OfficerCogstate appointed Dr. Kaycee Sink as Chief Medical Officer to lead Alzheimer's disease clinical trial support. She brings experience from Genentech and over 20 years in neurodegenerative disorders. The role aims to improve trial efficiency and commercialize cognitive assessment technologies.GlobeNewswireCogstate Announces Formation of Scientific Advisory BoardCogstate announced the formation of a Scientific Advisory Board comprising clinical and scientific experts in cognitive assessment and drug development. The board will be chaired by Eric Siemers, MD, and will support the company's strategy, innovation roadmaps, and R&D initiatives.